Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Up 10.0% in December

Gossamer Bio, Inc. (NASDAQ:GOSS) saw a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 7,020,000 shares, a growth of 10.0% from the November 30th total of 6,380,000 shares. Based on an average daily volume of 1,290,000 shares, the short-interest ratio is presently 5.4 days.

Institutional Investors Weigh In On Gossamer Bio

Hedge funds have recently bought and sold shares of the stock. Sequoia Financial Advisors LLC increased its stake in shares of Gossamer Bio by 26.7% during the third quarter. Sequoia Financial Advisors LLC now owns 118,500 shares of the company’s stock worth $117,000 after buying an additional 25,000 shares during the period. US Bancorp DE purchased a new stake in shares of Gossamer Bio in the 3rd quarter valued at approximately $39,000. Choreo LLC acquired a new stake in shares of Gossamer Bio in the 2nd quarter valued at $46,000. GSA Capital Partners LLP purchased a new stake in shares of Gossamer Bio during the 3rd quarter worth $67,000. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Gossamer Bio by 24.2% during the third quarter. The Manufacturers Life Insurance Company now owns 385,133 shares of the company’s stock worth $380,000 after purchasing an additional 74,920 shares in the last quarter. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Stock Up 2.7 %

Shares of NASDAQ:GOSS opened at $0.88 on Tuesday. The firm’s 50-day moving average is $0.81 and its two-hundred day moving average is $0.89. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. Gossamer Bio has a 1 year low of $0.50 and a 1 year high of $1.60. The firm has a market capitalization of $199.03 million, a PE ratio of -2.74 and a beta of 1.85.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04. The business had revenue of $9.48 million during the quarter, compared to analyst estimates of $4.52 million. Analysts predict that Gossamer Bio will post -0.28 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Gossamer Bio in a research note on Monday, November 11th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $9.20.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.